Chimerix picks up Michael Rogers, unveils $85M IPO plan

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Chimerix picks up Michael Rogers, unveils $85M IPO plan

Michael Rogers, formerly of Pharmasset, will join Chimerix as the company's chief development officer. The biotech company is on its way to picking up an $85 million initial public offering, and the FDA recently granted its antiviral drug CMX001 fast-track status. Rogers has experience bringing new drugs into the fray, and he will take that role in advancing the oral therapy CMX001 to play a part in the unmet antiviral market. More

Michael Rogers
Rogers joined Chimerix as its chief development officer.

Robert Hagemann
Hagemann stepped down as Quest Diagnostics' ($DGX) CFO.


Quest Diagnostics' ($DGX) CFO Robert Hagemann stepped down after more than 20 years at the company, almost 15 as CFO. Hagemann didn't say why he was leaving, but the change comes amid an organizational overhaul at Quest. Article

> Peter W. Schineller joined Alexza Pharmaceuticals ($ALXA) as the company's senior vice president and chief commercial officer. Schineller comes from Roche's ($RHHBY) Ventana Medical Systems most recently. Release

> Novella Clinical appointed Jon Gockerman as its senior medical director for oncology. Gockerman won the Leonard B. Tow Humanism in Medicine Award in 2012. More

> Amit Sharma joined Keryx Biopharmaceuticals ($KERX) as vice president of medical affairs. Sharma comes from Reata Pharmaceuticals, where he was the director of medical affairs. News

> Becton, Dickinson and Company ($BDX) brought on Ellen Strahlman to fill the newly created position of chief medical officer and senior vice president of research and development. Release

Adam Schechter, president of Merck's ($MRK) Global Human Health unit, will join LabCorp's board of directors on April 1. Schechter has been with Merck since 1988 and has overseen the Global Human Health business since 2010. Item

> Robert Doman took a position on the board of directors at Echo Therapeutics ($ECTE). Most recently, Doman was president and CEO of DUSA Pharmaceuticals. More

> Argos Therapeutics appointed Jean Lamarre to its board of directors. Lamarre is the president of Lamarre Consultants. News

> Three experts--Marc Feldmann, Gordon B. Mills and Alan Collis--will form a scientific advisory panel at Nuevolution to help the company with its drug-discovery programs. Release

Dr. Alan Robertson has left Australia's Pharmaxis and is being replaced by COO Gary Phillips, who was also appointed to the company's board of directors and served as a chief executive of Novartis. Story

Corinne Nevinny, general partner of early-stage venture firm LMNVC LLC, has been appointed to Avanir Pharmaceuticals' ($AVNR) board of directors. Release

Katrine Bosely, previously the CEO of Avila Therapeutics, has joined Genocea Biosciences' board of directors. Release

Stephen Farrell, CEO and director of Convey Health Solutions, has joined BioTime's board of directors. Release

Swiss Cytos Biotechnology ($CYTN) has appointed Matthias Alder executive vice president for corporate development and legal affairs and Cheryl Lassen as vice president for clinical development. Release

The following members of MethylGene's management team are leaving the company to pursue other interests: Jeffrey Besterman, executive vice president of research and development and chief scientific officer; Joe Walewicz, vice president of business and corporate development; and Klaus Kepper, vice president of finance and chief financial officer. Besterman's responsibilities have been assumed by CEO Charles Baum. COO Mark Gergen will fill in for Kepper and Walewicz in the interim. Release

Personal Genome Diagnostics is bringing Genzyme Oncology executive Antony Newton on board as chief commercial officer. Newton has served a 19-year career at Genzyme, where he held a number of roles in marketing, commercial development and drug development. He was most recently vice president in the oncology division. Release


Dr. Peter Sheehan joined Boston Therapeutics as consulting medical director. Sheehan has recently served as a senior faculty member at the Mount Sinai School of Medicine in New York City. Release

Japanese Santen Pharmaceutical has appointed Dr. Naveed Shams as president and CEO. Shams has served stints at Genentech, Novartis Ophthalmics, Opko Health, On Demand Therapeutics and Storz Ophthalmics. Release

Synta Pharmaceuticals has appointed Dr. Sumant Ramachandra as president of research and development. Previously, Ramachandra was senior vice president of research and development, regulatory and medical affairs, and chief scientific officer of Hospira ($HSP). Release

Affinium Pharmaceuticals has appointed Dr. Ed Mascioli as CEO, and Robert Radie is joining the company's board of directors. Mascioli has held positions as a senior executive at Pfizer ($PFE), Dapis Capital, Peptimmune, and MPM Capital. Radie is currently president and CEO of Egalet. Release

Medical Devices

> Orthofix International brought on Brad Mason as its president and CEO. Mason is named inventor on 38 issued patents in the orthopedic product arena. Release

> AtriCure ($ATRC) appointed Robert S. White to its board of directors. White is currently president and CEO of Tyrx. More


Lantheus Medical Imaging has appointed Dr. Cesare Orlandi as the company's new chief medical officer. Orlandi most recently served as senior vice president and chief medical officer of TransTech Pharma. Release


James Taylor has joined INC Research as vice president of clinical development. Taylor is making the move from Pfizer ($PFE), where he most recently served as vice president of global clinical trial management. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.